Axon Enterprise, Inc. (NASDAQ:AXON) Receives Average Rating of "Moderate Buy" from Analysts

Axon Enterprise, Inc. (NASDAQ:AXON - Get Free Report) has earned a consensus rating of "Moderate Buy" from the thirteen research firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and twelve have given a buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $427.83.

A number of brokerages have issued reports on AXON. Craig Hallum boosted their price target on shares of Axon Enterprise from $370.00 to $376.00 and gave the stock a "buy" rating in a research note on Wednesday, August 7th. JMP Securities increased their target price on shares of Axon Enterprise from $430.00 to $500.00 and gave the stock a "market outperform" rating in a report on Thursday, October 31st. Bank of America started coverage on shares of Axon Enterprise in a research report on Wednesday, July 17th. They issued a "buy" rating and a $380.00 price target for the company. Jefferies Financial Group assumed coverage on Axon Enterprise in a research report on Wednesday, July 17th. They set a "buy" rating and a $385.00 price objective on the stock. Finally, The Goldman Sachs Group lifted their target price on Axon Enterprise from $385.00 to $441.00 and gave the company a "buy" rating in a report on Wednesday, October 23rd.

Insider Activity

In related news, President Joshua Isner sold 25,811 shares of the company's stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $359.84, for a total value of $9,287,830.24. Following the completion of the transaction, the president now directly owns 228,166 shares of the company's stock, valued at $82,103,253.44. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, Director Michael Garnreiter sold 1,000 shares of Axon Enterprise stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $437.98, for a total transaction of $437,980.00. Following the sale, the director now owns 26,259 shares in the company, valued at approximately $11,500,916.82. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, President Joshua Isner sold 25,811 shares of the company's stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $359.84, for a total value of $9,287,830.24. Following the completion of the sale, the president now directly owns 228,166 shares of the company's stock, valued at approximately $82,103,253.44. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 369,172 shares of company stock worth $136,270,842. 6.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Axon Enterprise

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Blue Trust Inc. increased its holdings in shares of Axon Enterprise by 987.5% in the 2nd quarter. Blue Trust Inc. now owns 87 shares of the biotechnology company's stock valued at $27,000 after acquiring an additional 79 shares during the period. Quent Capital LLC increased its stake in Axon Enterprise by 1,875.0% in the third quarter. Quent Capital LLC now owns 79 shares of the biotechnology company's stock valued at $32,000 after purchasing an additional 75 shares during the period. Asset Dedication LLC purchased a new stake in shares of Axon Enterprise in the second quarter valued at about $47,000. Planning Capital Management Corp raised its holdings in shares of Axon Enterprise by 83.3% in the third quarter. Planning Capital Management Corp now owns 121 shares of the biotechnology company's stock valued at $48,000 after buying an additional 55 shares during the last quarter. Finally, Friedenthal Financial acquired a new stake in shares of Axon Enterprise during the third quarter worth about $51,000. Hedge funds and other institutional investors own 79.08% of the company's stock.

Axon Enterprise Trading Up 2.1 %

Shares of NASDAQ AXON traded up $12.96 during trading on Monday, reaching $616.14. The stock had a trading volume of 1,792,632 shares, compared to its average volume of 544,227. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.52 and a current ratio of 2.88. The company has a market cap of $46.56 billion, a P/E ratio of 158.14, a PEG ratio of 15.15 and a beta of 0.94. Axon Enterprise has a fifty-two week low of $216.73 and a fifty-two week high of $624.84. The business's 50-day moving average price is $414.16 and its 200-day moving average price is $347.59.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.